Tenecteplase Shortens Stroke Treatment and Transfer Times
🔓 Free Teaser Analysis Neurology / Neuropharmacology Confirmatory Grade: Low
Warach SJ, Weber JM, Alhanti B, et al.
Jul 13, 2026 · Published in: JAMA Network Open
Tenecteplase speeds up stroke thrombolysis compared to alteplase.
DAPT Shows Promise in Specific Minor Stroke Cases
Analysis Neurology / Neuropharmacology
Cui Y, Li ZA, He C, et al.
Oct 6, 2026 · Published in: Brain and Behavior
Could DAPT be superior to alteplase for certain minor strokes?
Bleeding May Outpace Ischemic Recurrence in Young Stroke Survivors
Analysis Anticoagulation / Hematology Hypothesis-generating Grade: Low
Rasing A, Verburgt E, Ekker MS, et al.
Sep 24, 2026 · Published in: JAMA Network Open
Also in Neurology / Neuropharmacology
Young stroke survivors face significant bleeding risk on antithrombotic therapy.
RESTART tICrH: Randomized Test of 1- vs 4-Week DOAC Resumption
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Very Low
Edlmann E, Kannan S, Wright L, et al.
Sep 17, 2026 · Published in: BMJ Open
Also in Anticoagulation / Hematology
When should DOACs restart after brain bleeding? This trial aims to find out.
PRUs Track CYP2C19 Genotype but Not Stroke Recurrence
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Low
Stone RM, Smith A, Gunter S, et al.
Sep 11, 2026 · Published in: Pharmacotherapy
PRUs may identify clopidogrel resistance in stroke patients without genotyping.
AAN and AHS Release Updated Adult Migraine Prevention Pharmacotherapy Guideline
★ Editor's Pick Guideline Neurology / Neuropharmacology Practice-changing Grade: Moderate
Aug 31, 2026 · Published in: Neurology
New guidelines optimize migraine prevention with personalized strategies.
Rethinking Rigid DOAC Exclusion Rules for Stroke Thrombolysis
★ Editor's Pick Analysis Anticoagulation / Hematology Hypothesis-generating Grade: Very Low
Zupan M, Šabovič M, Kermer P, et al.
Aug 21, 2026 · Published in: Frontiers in Neurology
Also in Neurology / Neuropharmacology
Reassessing IVT in recent DOAC exposure for stroke care.
Breakthrough Stroke on Anticoagulation: Identifiable Causes Double Recurrence Risk
Analysis Anticoagulation / Hematology Hypothesis-generating Grade: Low
De Santis F, Foschi M, Gabriele F, et al.
Aug 16, 2026 · Published in: Journal of Neurology
Also in Neurology / Neuropharmacology
Ischemic strokes occur even with anticoagulation; drug interactions may be key.
NOACs Beat Warfarin on Cognition and Outcomes in AF Plus Alzheimer's
Analysis Anticoagulation / Hematology Confirmatory Grade: Low
Zhu N, Xu H, Garcia-Ptacek S, et al.
Aug 12, 2026 · Published in: European Heart Journal
Also in Neurology / Neuropharmacology
NOACs slow cognitive decline in AF with Alzheimer's disease.
Marine-Derived Drugs in Alzheimer's: Modest, Inconsistent Cognitive Signals
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Low
Song Z, Xie Y, Zhu H, et al.
Aug 10, 2026 · Published in: Therapeutic Advances in Neurological Disorders
Marine-derived drugs show potential but varied cognitive effects in Alzheimer's.
Perampanel and levetiracetam both control SeLECTS with minor sleep differences
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Very Low
Yan L, Xie L, Li T, et al.
Aug 8, 2026 · Published in: Epilepsy & Behavior : E&B
PER may enhance sleep in children with SeLECTS.
Real-world lecanemab in Chinese patients: low ARIA, financial-driven discontinuation
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Low
Wu H, Chen Q, Fang M, et al.
Aug 6, 2026 · Published in: Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Lecanemab shows safety but no cognitive boost in real-world AD study.
Extension Data Bolster Case Against Amyloid Therapy Coverage Restrictions
Analysis Neurology / Neuropharmacology Confirmatory Grade: Low
Boustani M, Klein EG, Zimmer JA, et al.
Aug 5, 2026 · Published in: Alzheimer's & Dementia
Amyloid therapies show promise in Alzheimer's treatment.
THC:CBD Extract Modestly Eases Subjective MS Spasticity
Analysis Neurology / Neuropharmacology Confirmatory Grade: Low
Liang D, Weir DL, Thevasahayam S, et al.
Aug 4, 2026 · Published in: British Journal of Clinical Pharmacology
Antidiabetic drug safety profiles expand significantly post-marketing.
Cladribine tablets sustain remission through two treatment-free years
Analysis Neurology / Neuropharmacology Confirmatory Grade: Low
De Stefano N, Vermersch P, Wiendl H, et al.
Aug 4, 2026 · Published in: Multiple Sclerosis (Houndmills, Basingstoke, England)
Also in Ambulatory Care / MTM
Cladribine tablets show promise for sustained treatment-free remission in RMS.